Table 1 Baseline characteristics and therapeutic regimens during follow-up of 36 RA patients with hepatitis B virus (HBV) carrier state ▲
All Patients (n = 36) | Baseline serum HBV DNA | ||
|---|---|---|---|
Undetectable (n = 20) | Detectable (n = 16) | ||
Demographic characters | |||
Age (years) | 46 ± 15 | 45 ± 15 | 48 ± 16 |
Female proportion | 28 (78%) | 14 (70%) | 14 (88%) |
Disease status | |||
Disease duration (months), median (range) | 21 (2 ~ 360) | 11 (2 ~ 240) | 24 (2 ~ 360) |
Past history of hepatitis | 9 (25%) | 5 (25%) | 4 (25%) |
DAS28-crp, mean ± SD (range) | 4.2 ± 1.6 (1.2 ~ 7.6) | 4.4 ± 1.7 (1.2 ~ 7.4) | 3.9 ± 1.6 (1.7 ~ 7.6) |
RF positive rate | 21 (58%) | 11 (55%) | 10 (63%) |
Anti-CCP antibody positive rate | 17 (47%) | 12 (60%) | 5 (31%) |
CRP (mg/L) | 25 ± 33 | 28 ± 35 | 20 ± 32 |
ESR (mm/1 h) | 49 ± 43 | 55 ± 48 | 40 ± 35 |
ALT (U/L) | 19 ± 10 | 17 ± 12 | 21 ± 6# |
Total bilirubin (μmol/L) | 8 ± 4 | 8 ± 2 | 11 ± 5 |
Therapeutic regimens during follow-up | |||
MTX | 3 (8%) | 2 (10%) | 1 (6%) |
LEF* | 2 (6%) | 2 (10%) | 0 (0%) |
HCQ | 1 (3%) | 0 (0%) | 1 (6%) |
MTX + LEF | 5 (14%) | 3 (15%) | 2 (13%) |
MTX + SSZ | 3 (8%) | 2 (10%) | 1 (6%) |
MTX + HCQ | 10 (28%) | 4 (20%) | 6 (38%) |
MTX + HCQ + SSZ | 12 (33%) | 7 (35%) | 5 (31%) |
Low-dose Corticosteroid | 29 (81%) | 15 (75%) | 14 (88%) |
TNF-α antagonist△ | 4 (11%) | 4 (20%) | 0 |